MX428336B - Tratamiento de hidradenitis con inhibidores de quinasa - Google Patents

Tratamiento de hidradenitis con inhibidores de quinasa

Info

Publication number
MX428336B
MX428336B MX2022002995A MX2022002995A MX428336B MX 428336 B MX428336 B MX 428336B MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 428336 B MX428336 B MX 428336B
Authority
MX
Mexico
Prior art keywords
hidradenitis
treatment
kinase inhibitors
jak
analogues
Prior art date
Application number
MX2022002995A
Other languages
English (en)
Other versions
MX2022002995A (es
Inventor
Andrew Fensome
Brian Stephen Gerstenberger
Dafydd Rhys Owen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022002995A publication Critical patent/MX2022002995A/es
Publication of MX428336B publication Critical patent/MX428336B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Métodos para tratar hidradenitis supurativa usando compuestos y análogos que inhiben determinadas quinasas, que incluyen la quinasa Janus (JAK).
MX2022002995A 2019-09-11 2020-09-08 Tratamiento de hidradenitis con inhibidores de quinasa MX428336B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899133P 2019-09-11 2019-09-11
PCT/IB2020/058333 WO2021048736A1 (en) 2019-09-11 2020-09-08 Treatment of hidradenitis with jak inhibitors

Publications (2)

Publication Number Publication Date
MX2022002995A MX2022002995A (es) 2022-06-02
MX428336B true MX428336B (es) 2025-11-13

Family

ID=72473596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002995A MX428336B (es) 2019-09-11 2020-09-08 Tratamiento de hidradenitis con inhibidores de quinasa

Country Status (14)

Country Link
US (1) US12569487B2 (es)
EP (1) EP4028007B1 (es)
JP (1) JP2021042204A (es)
KR (1) KR20220059519A (es)
CN (1) CN114667148A (es)
AR (1) AR119942A1 (es)
AU (1) AU2020347561B2 (es)
BR (1) BR112022004221A2 (es)
CA (1) CA3153676A1 (es)
ES (1) ES3019413T3 (es)
IL (1) IL291146B1 (es)
MX (1) MX428336B (es)
TW (1) TWI846947B (es)
WO (1) WO2021048736A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220059519A (ko) 2019-09-11 2022-05-10 화이자 인코포레이티드 키나제 억제제에 의한 한선염의 치료
WO2023178001A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis
WO2024173764A1 (en) * 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
WO2025257327A1 (en) * 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534233A (ja) 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
NO2721710T3 (es) 2014-08-21 2018-03-31
US10973913B2 (en) * 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
MX383747B (es) 2016-02-24 2025-03-14 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
TWI763722B (zh) * 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク,インコーポレイテッド 化膿性汗腺炎の処置
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
WO2019191679A1 (en) * 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
KR20260080448A (ko) * 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
KR20220059519A (ko) 2019-09-11 2022-05-10 화이자 인코포레이티드 키나제 억제제에 의한 한선염의 치료

Also Published As

Publication number Publication date
US12569487B2 (en) 2026-03-10
AR119942A1 (es) 2022-01-19
ES3019413T3 (en) 2025-05-20
TW202123940A (zh) 2021-07-01
IL291146B1 (en) 2026-08-01
EP4028007A1 (en) 2022-07-20
JP2021042204A (ja) 2021-03-18
CA3153676A1 (en) 2021-03-18
US20250032492A1 (en) 2025-01-30
IL291146A (en) 2022-05-01
BR112022004221A2 (pt) 2022-05-31
KR20220059519A (ko) 2022-05-10
CN114667148A (zh) 2022-06-24
EP4028007B1 (en) 2025-03-26
WO2021048736A1 (en) 2021-03-18
AU2020347561A1 (en) 2022-04-14
TWI846947B (zh) 2024-07-01
MX2022002995A (es) 2022-06-02
NZ786079A (en) 2025-10-31
AU2020347561B2 (en) 2026-02-26